Adverse Event Reporting of Four Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: A Real-World Study Based on the FDA Adverse Event Reporting System
January 2024
in “
Frontiers in Pharmacology
”
TLDR These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
This study analyzed 65,792 adverse event reports from the FDA Adverse Event Reporting System for four anti-CGRP monoclonal antibodies used in migraine prevention. Erenumab had the most reports, with common adverse events including constipation (17.93%) and alopecia (7.23%). Galcanezumab frequently caused injection site pain (24.37%). New adverse events not listed in drug instructions, such as Raynaud’s phenomenon and weight increase, were identified. The study emphasizes the importance of monitoring these drugs' adverse events to guide clinical decisions, noting that many adverse events were reported in female patients, which aligns with the higher prevalence of migraines in women.
